| Application no. and date | 17194307.9 (espacenet) (Federated) (European Patent Register), 20120725 | | Patent/reg. no. and date | DK/EP 3333161, 20200219 | | Publication date | 20180613 | | Priority no. and date | US 201161512061 P, 20110727, US 201261591363 P, 20120127 | | EP pub. no. and date |
EP 3333161 20180613 | | Effective date | | | Applicant/owner | Astrazeneca AB, 151 85 Södertälje, SE | | Applicant ref. no. | 1550198 | | Inventor | BUTTERWORTH, Sam, c/o AstraZeneca Intellectual Property, AstraZeneca
Alderley Park
Macclesfield, Cheshire SK10 4TG, GB,
WARD, Richard, Andrew, AstraZeneca
Darwin Building Cambridge Science Park, Milton
Road
Cambridge, Cambridgeshire CB4 0WG, GB,
FINLAY, Maurice, Raymond, Verschoyle, AstraZeneca, Darwin Building
Cambridge Science Park, Milton Road
Cambridge, Cambridgeshire CB4 0WG, GB,
KADAMBAR, Vasantha, Krishna, AstraZeneca
Alderley Park
Macclesfield, Cheshire SK10 4TG, GB,
CHINTAKUNTLA, Chandrasekhara, Reddy, AstraZeneca
Alderley Park
Macclesfield, Cheshire SK10 4TG, GB,
MURUGAN, Andiappan, AstraZeneca
Alderley Park
Macclesfield, Cheshire SK10 4TG, GB,
CHUAQUI, Claudio, Edmundo, AstraZeneca
35 Gatehouse Drive
Waltham, MA 02451, US,
REDFEARN, Heather, Marie, AstraZeneca
Charter Way
Macclesfield, Cheshire SK10 2NA, GB | | Representative | RWS Group, RWS Compass House
Vanwall Business Park, Vanwall Road
Maidenhead, Berkshire
SL6 4UB, GB | | Opponent | | | IPC Class | A61K 31/437 (2006.01) , A61K 31/506 (2006.01) , A61P 35/00 (2006.01) , C07D 401/02 (2006.01) , C07D 471/04 (2006.01) | | Title | 2-(2,4,5-SUBSTITUERET ANILIN)-PYRIMIDINDERIVATER SOM EGFR-MODULATORER, DER ER ANVENDELIGE TIL BEHANDLING AF CANCER | | Int. application no. | | | Int. publication no. | | | Related patent (certificate) | | | Status | DK/EP patent | | Pædiatrisk forlængelse | - | | Udløbsdato for pædiatrisk forlængelse | - |
|
